|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-2.99/-1.90
|
企業價值
74.26M
|
資產負債 |
每股賬面淨值
2.78
|
現金流量 |
現金流量率
--
|
損益表 |
收益
0
|
每股收益
--
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/12/25 01:59 EST
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The initial focus of the company is on advancing AV-101, a dry powderinhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. |